Proteomics International Laboratories Ltd (PIQ.AX) September 2023 Quarterly Activities Report and Appendix 4C
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2023 and subsequent to the period end.
- US Medicare sets reimbursement price for PromarkerD and Australian regulatory decision: Major commercial milestone achieved with the diabetic kidney disease (DKD) test assigned a payment rate of US$390 in the United States
- Oesophageal cancer test presented at World Congress for Esophageal Diseases: PromarkerEso blood test shows strong discrimination of oesophageal adenocarcinoma - analysis commenced to confirm the clinical performance of the test in independent cohorts
- OxiDx technology secures patent in Japan: Landmark patent is the first to grant of a new family of patents which greatly extend the intellectual property protection for OxiDx's nextgeneration diagnostics technology
- Sector related developments for PromarkerD: Complementary diagnostics - empagliflozin and semaglutide offer new drug treatments for DKD; Kidney Research UK declare a public health emergency
Proteomics International's activities fall into three key areas:
(i) commercialisation of PromarkerD, the predictive test for diabetic kidney disease (DKD)
(ii) Precision diagnostic tests in development - the PromarkerTM pipeline
(iii) Specialist accredited analytical services on a commercial basis
*To view the full Quarterly Report, please visit:
https://abnnewswire.net/lnk/JD43ZD10
Dr Richard Lipscombe Managing Director Proteomics International Laboratories Ltd T: +61 8 9389 1992 E: enquiries@proteomicsinternational.com Dirk van Dissel Investor Relations & Corporate Advisor Candour Advisory T: +61 408 326 367 E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Euroz Hartleys T: +61 8 9488 1400 E: kmoss@eurozhartleys.com
News Provided by ABN Newswire
